Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Sees Large Growth in Short Interest

Posted by Stanley Muller on Aug 25th, 2026

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Get Free Report) was the recipient of a significant increase in short interest in the month of August. As of August 14th, there was short interest totaling 201,048 shares, an increase of 2,279.8% from the July 30th total of 8,448 shares. Approximately 4.2% of the shares of the stock are short sold. Based on an average trading volume of 399,785 shares, the short-interest ratio is presently 0.5 days.

Institutional Investors Weigh In On Sonoma Pharmaceuticals

A hedge fund recently raised its stake in Sonoma Pharmaceuticals stock. DRW Securities LLC lifted its stake in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA – Free Report) by 257.2% in the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 60,977 shares of the company’s stock after purchasing an additional 43,907 shares during the quarter. DRW Securities LLC owned about 3.59% of Sonoma Pharmaceuticals worth $222,000 at the end of the most recent reporting period. Institutional investors own 1.95% of the company’s stock.

Sonoma Pharmaceuticals Trading Up 0.7%

SNOA traded up $0.01 during trading hours on Tuesday, hitting $1.35. The company’s stock had a trading volume of 47,340 shares, compared to its average volume of 135,611. The stock has a market cap of $6.47 million, a price-to-earnings ratio of -1.11 and a beta of 1.28. The business’s 50-day moving average price is $1.22 and its 200-day moving average price is $1.72. Sonoma Pharmaceuticals has a 12 month low of $0.85 and a 12 month high of $4.87.

Sonoma Pharmaceuticals (NASDAQ:SNOA – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.30) by $0.32. Sonoma Pharmaceuticals had a negative net margin of 10.33% and a negative return on equity of 21.41%. The business had revenue of $6.41 million during the quarter, compared to analyst estimates of $4.99 million.

Analyst Ratings Changes

Separately, Weiss Ratings lowered shares of Sonoma Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of “Sell”.

View Our Latest Analysis on Sonoma Pharmaceuticals

Sonoma Pharmaceuticals Company Profile

(Get Free Report)

Sonoma Pharmaceuticals, Inc is a specialty dermatology company focused on developing and commercializing topical prescription and over-the-counter products for inflammatory and infectious skin conditions. Publicly traded on Nasdaq under the symbol SNOA, the company concentrates its efforts on areas such as acne, rosacea, dermatitis and wound care, aiming to provide physicians and patients with innovative treatment options.

At the heart of Sonoma’s technology platform lies its proprietary Triphasic drug delivery system, which enables the timed release of active ingredients through three distinct gel phases.